Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome*
peer-reviewed · Molecular & Cellular Proteomics · 2018
| Date | 2018-12-01 |
| Type | peer-reviewed |
| Venue | Molecular & Cellular Proteomics |
| Publisher | Elsevier BV |
| Contribution | downstream-application |
| DOI | 10.1074/mcp.ra118.000877 |
| Citations (OpenAlex) | 105 |
| Venue 2-year citedness | 4.69 |
Preprint version: Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome (2018-03-26, bioRxiv)
Abstract
Spliced peptides are short protein fragments spliced together in the proteasome by peptide bond formation. True estimation of the contribution of proteasome-spliced peptides (PSPs) to the global human leukocyte antigen (HLA) ligandome is critical. A recent study suggested that PSPs contribute up to 30% of the HLA ligandome. We performed a thorough reanalysis of the reported results using multiple computational tools and various validation steps and concluded that only a fraction of the proposed PSPs passes the quality filters. To better estimate the actual number of PSPs, we present an alternative workflow. We performed de novo sequencing of the HLA-peptide spectra and discarded all de novo sequences found in the UniProt database. We checked whether the remaining de novo sequences could match spliced peptides from human proteins. The spliced sequences were appended to the UniProt fasta file, which was searched by two search tools at a false discovery rate (FDR) of 1%. We find that 2-6% of the HLA ligandome could be explained as spliced protein fragments. The majority of these potential PSPs have good peptide-spectrum match properties and are predicted to bind the respective HLA molecules. However, it remains to be shown how many of these potential PSPs actually originate from proteasomal splicing events.
Methods and tools
- Proteasomal spliced peptide estimation: Uses de novo sequencing of HLA-I peptide spectra, filtered against UniProt and matched to spliced candidates, to estimate how many ligands are proteasome-spliced.
Methods it uses
- PEAKS: Commercial DP-based de novo
Data deposited
- Estimating the Contribution of Proteasomal Spliced Peptides to the HLA-I Ligandome (as deposited) · PXD010793
Data used
- Fully unsupervised identification of HLA-I motifs (as deposited) · PXD005231
Cites (2)
- De Novo Sequencing and Homology Searching (2012) crossref
- PEAKS: powerful software for peptide de novo sequencing by tandem mass spectrometry (2003) crossref
Cited by (7)
- Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics (2023) crossref
- Characterization of Proteasome-Generated Spliced Peptides Detected by Mass Spectrometry (2022) crossref
- Digging deeper into the immunopeptidome: characterization of post-translationally modified peptides presented by MHC I (2021) crossref
- Elucidation of the Signatures of Proteasome-Catalyzed Peptide Splicing (2020) crossref
- Identification of the Cryptic HLA-I Immunopeptidome (2020) crossref
- Uncovering Thousands of New Peptides with Sequence-Mask-Search Hybrid De Novo Peptide Sequencing Framework (2019) crossref
- Combination of Proteogenomics with Peptide De Novo Sequencing Identifies New Genes and Hidden Posttranscriptional Modifications (2019) crossref